Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms.

Swati GoelChiara PaoliAlessandra IurloArturo PereiraFabio EfficaceTiziano BarbuiAyalew TefferiAlessandro M VannucchiFrancisco Cervantes

Published in: European journal of haematology (2017)

Physicians and pharmaceutical companies involved in clinical trials with patients with hematological diseases should be aware of these problems and make efforts to attenuate the socioeconomic burden of participation in the trials.

Keyphrases

clinical trial
physical activity
primary care
mental health
phase ii
risk factors
double blind
quality improvement